Rallying Trend: Genetic Technologies (GENE) Shares Maintain Momentum

The shares of Genetic Technologies Limited (NASDAQ: GENE) sustained their upward momentum on Friday, demonstrating a 2.50% increase to settle at $3.32. This ascent follows a notable surge exceeding 8% in the preceding session. The surge in GENE shares coincided with the anticipation of a significant interview slated for broadcast the subsequent day.

RedChip Companies presented an interview featuring Genetic Technologies (GENE) on the RedChip Small Stocks, Big Money program. It was a sponsored segment aired on Bloomberg TV, this Saturday, April 13th with an estimated 73 million households across the United States.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Furthermore, the previous day’s uptick was spurred by the announcement of a significant endeavor. Genetic Technologies is launching a clinical implementation study in collaboration with breast imaging centers across New York, Miami, and Houston. This endeavor aims to pilot the integration of geneType into breast imaging centers, thereby enhancing the coherence of care in a domain currently characterized by some fragmentation.

This initiative represents a noteworthy stride in personalized medicine, particularly concerning breast density notification and supplemental screening options for women at elevated risk. The inception of this groundbreaking study is rooted in feedback from prominent employer and payer groups in the United States, acknowledging women’s healthcare, particularly in the domain of breast cancer, as harboring the most auspicious health and economic benefits.

Leading clinicians at the forefront of this study include Sheldon M. Feldman, MD, FACS, Director of breast cancer services at Montefiore Medical Center, and Elizabeth Etkin-Kramer, M.D., FACOG, OB-GYN, and assistant professor at Florida International University. Dr. Etkin-Kramer is the founder of Yodeah.org and is affiliated with Mount Sinai Medical Center in Miami.

Accurate breast cancer risk assessment is imperative for ensuring high-quality care at distinguished breast centers. Through geneType, Genetic Technologies is revolutionizing risk assessment beyond the current gold standard of care. The integration of geneType into breast imaging centers represents a significant paradigm shift in the evaluation of breast cancer risk.

Ultimately, Genetic Technologies’ pioneering study heralds a new epoch of precision medicine in the battle against breast cancer, offering screening and risk-reduction opportunities by identifying individuals at higher risk.

Most Popular